DUSP6 depletion and a capecitabine–neratinib combination
Cell-based study · HER2+ MDA-MB-453 breast cancer cells; scrambled siRNA control and DUSP6 knockdown, with or without the drug combination. [1]
DUSP6 depletion increased sensitivity to the capecitabine–neratinib combination after 48 h. The experiment evaluates a combination and genetic perturbation; it does not isolate capecitabine monotherapy activity or establish its metabolic activation.
| Endpoint | Reported result | Reference |
|---|---|---|
| Cell viability after 48 h | WST-1 relative viability DUSP6 knockdown plus capecitabine/neratinib reduced viability relative to the drug combination or knockdown alone (****p<0.0001). | [1] |
Literature-Reported Treatment Conditions
- Exposure duration
- 48 h drug treatment
- Method
- WST-1 assay; DUSP6 siRNA perturbation compared with scrambled control.
- Vehicle
- DMSO; final concentration did not exceed 0.1% [v/v] in treatments.
- Co-treatment
- Capecitabine plus neratinib, with or without DUSP6 knockdown.
- Reported limits
- Drug doses are not specified in Figure 4E/caption or the retrieved relevant methods. Linked Figure 4 source data returned HTML, not a usable ZIP. Exact siRNA identity in Table EV1 was not retrieved; no sequence-specific mechanism claim is adopted.
Methods and source locations
Compound reported in the paper: Capecitabine; Compound label in the paper: Capecitabine with neratinib
Qualitative response to the named drug combination under DUSP6 depletion; no capecitabine-only potency, lot equivalence or clinical efficacy claim.
Reagents; Cell Culture and Transfections; Cell growth assays; Results paragraph on DUSP6 depletion and capecitabine; Figure 4E and caption
Cell viability after 48 h: Three independent experiments, each in triplicate; one-way ANOVA followed by Tukey multiple comparisons (Figure 4E caption). — Reagents; Cell Culture and Transfections; Cell growth assays; Results paragraph on DUSP6 depletion and capecitabine; Figure 4E and caption